The Health Resources and Services Administration (HRSA) released a proposed rule on Sept. 24 that would require Federally Qualified Health Centers (FQHCs) participating in the 340B Drug Pricing Program to provide low-income health center patients access to insulin and/or injectable epinephrine at no more than the 340B price. This follows Executive Order 13937, which President Trump signed in July [see Washington Highlights, July 28].
FQHCs enrolled in the 340B Program would be required to make 340B-acquired insulin and injectable epinephrine available to low-income health center patients. Low-income patients are defined as individuals or families with annual incomes at or below 350% of the Federal Poverty Guidelines. Patients enrolled in an insurance coverage with a high cost sharing for either drug, a high deductible, or are uninsured, would be charged no more than the 340B price to acquire the drug, plus a minimal administration fee. FQHCs would not be required to charge third party payers the discounted price.
Public comments are due October 28, 2020.